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Introduction
The large case-control study INTERHEART [1], which
enrolled over 15 thousand patients from every inhabited
continent, showed that nine modifiable risk factors
accounted for at least 90% of the risk of myocardial
infraction, which suggested that the role of additional risk
factors in the prediction of coronary events was minor.
However, it is estimated that about 20% of patients with
cardiovascular events do not have any of the main cardio-
vascular risk factors and 50% have only one of them [2]. 
So far about 200 new risk factors have been identified.
Many of them do not have standardized methods of
measurement or are not associated with cardiovascular
risk independently of the main cardiovascular risk factors. 
The search for new plasma risk factors which could
improve detection of subjects at risk of atherosclerosis
and its thromboembolic complications was bi-directional
and comprised:
1) assessment of the markers of inflammation and
endothelial function, because atherogenesis is a chronic
inflammatory process of the arterial wall,
2) assessment of the markers of activation of thrombosis
and fibrinolysis, because myocardial infarction and
ischaemic stroke are consequences of thromboembolic
processes. 
The so-called new risk factors for which the most
reliable evidence of their association with the risk of
cardiovascular events is available [3] are as follows.
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Serologic factors
1) lipid risk factors:
a) apolipoprotein B (Apo B)
b) lipoprotein (a) [Lp(a)]
c) lipoprotein-associated phospholipase A2 (Lp-PLA2)
d) oxidised LDL
2) inflammatory risk factors:
a) C-reactive protein (CRP)
b) serum amyloid A (SAA)




4) asymmetric dimethylarginine (ADMA)
5) matrix metalloproteinase 9 (MMP-9)
6) tissue inhibitor of metalloproteinase 1 (TIMP-1)
7) glutathione peroxidase activity
Structural and functional risk factors
1) intima-media thickness of carotid arteries (IMT)








3) tissue plasminogen activator – tPA and plasminogen
activator inhibitor 1 (PAI-1)
4) von Willebrand factor (vWF)
Regarding the current guidelines of the European
Society of Cardiology, American Heart Association and
American College of Cardiology, it is not recommended to
assess the so-called new risk factors in order to improve
prediction of cardiovascular risk.
No methods of clinically significant modification of
these factors are currently available.
It is unlikely that one new risk factor will improve
prediction models based on the traditional risk factors,
whose position is invariably strong. It is probable
however that in the future a panel of biomarkers will be
available, which will make possible an individualized
approach to the therapy of cardiovascular diseases. 
Guidelines
1. Haemostatic factors. The following factors have been
shown to increase cardiovascular disease (CVD) risk:
fibrinogen (an increase in plasma fibrinogen concentration
of 1 g/l increases the risk of CVD incidence twofold),
clotting factor VII, von Willebrand factor (vWF),
plasminogen activator inhibitor (PAI-1), tissue plasminogen
activator (tPA). These factors can usually be improved by
standard preventive interventions. In some conditions it is
justified to introduce pharmacological treatment that
influences the haemostatic system as a preventive tool.
Currently no specific intervention aimed at reduction of
CVD risk by modulating the aforementioned haemostatic
factors in the general population is available and their
routine measurement to estimate CVD risk is not
recommended.
2. Inflammatory markers. Elevated plasma levels of
CRP >3 mg/dl increase the risk of CVD events by about
50%. Higher CVD risk has also been attributed to some
other inflammatory markers such as: interleukins (IL-6,
IL-10, IL-18), tumour necrosis factor α (TNF-α), soluble
CD40 ligand (sCD40L), matrix metalloproteinase 9
(MMP-9), myeloperoxidases. In clinical practice it is not
recommended to measure the aforementioned
inflammatory markers in order to estimate CVD risk.
3. Homocysteine. Homocysteine plasma levels
elevation of 3 μmol/l increases the risk of coronary heart
disease and stroke by about 11–30% and about 20%
respectively. A diet including at least 400 μg of folic acid
per day reduces blood homocysteine concentration;
however, no beneficial effect of folic acid supplementation
on CVD risk has been achieved. In clinical practice it is not
recommended to measure the homocysteine level in order
to estimate CVD risk.
4. Imaging methods such as B-mode ultrasound
measurement of intima-media thickness and
endothelium dependent dilation of the vessel wall as
well as a quantitative assessment of artery calcification
by multislice computed tomography may contribute to
estimation of the extent of atherosclerosis, to diagnosis
of CVD in asymptomatic subjects and to assessment of
CVD risk. The role of these methods in population
screening programmes has not been established.
5. Intima-media thickness (IMT) of carotid arteries
reflects progression of the atherosclerotic process and
may be helpful in prediction of cardiovascular events in
asymptomatic patients at intermediate CVD risk. IMT
ranging from 0.9 to 1.5 mm is classified as intima-media
complex thickening while IMT >1.5 mm is classified as an
atherosclerotic plaque. 
6. Coronary calcium score (CS) equal to zero (CS=0)
indicates low risk of cardiovascular events in asymptomatic
subjects while in patients with symptoms of ischaemic
heart disease it allows the presence of significant coronary
artery stenosis to be excluded with high probability.
7. Heart rate – lower heart rate is associated with
lower CVD risk. Physically active subjects have lower
heart rate, and an appropriate level of physical activity is
one of the main recommendations in primary and
secondary prevention of CVD. An undoubted indication
for pharmacological intervention is clinically significant
elevated heart rate. However, it is not recommended to
lower the heart rate by pharmacological means in order
to decrease CVD risk in primary prevention. 
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8. Influenza vaccination – decreases the risk of acute
cardiovascular events in patients with established
cardiovascular disease. These subjects may benefit from
vaccination unless they have a contraindication to
receiving the vaccine. Vaccination with intramuscularly
administered vaccine should be prescribed annually,
optimally before the winter peak in influenza activity. 
9. Assessment of genetic predisposition to
cardiovascular diseases on the basis of family history is
required in primary prevention. Premature CVD in first
degree (parents, siblings, children) male relatives <55
years and female relatives <65 years is associated with at
least twofold increase in CVD risk. The presence of CVD
in other relatives has lower significance.
Genetic studies should be prescribed only in patients
suspected of rare monogenic diseases, especially familiar
hypercholesterolaemia. 
10. Air pollution, such as a high concentration of small
diameter particles <2.5 μm, is associated with increased
CVD risk. Air quality monitoring and restrictions on
emissions of exhaust fumes from industry should be part
of a population strategy in prevention of CVD. 
Currently, no efficient methods that could be useful in
individual counselling on air pollution in clinical practice
are available. 
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The Polish version of the guidelines as well as the introductory article
and comments from specialists and experts can be read in the seventh
issue of Forum Profilaktyki and on the website www.pfp.edu.pl. Authors
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Errata. We wrześniowym numerze Kardiologii Polskiej
w tekście Polish Forum for Prevention Guidelines on Arte-
rial Hypertension Rycina 2. (strona 1139) została wydruko-











Figure 2. Possible combinations between some
classes of antihypertensive drugs
The preferred combinations in the general hypertensive population
are represented as thick lines. 
The frames indicate classes of agents proven to be beneficial in
controlled intervention trials.
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